Ursula Klingmueller

Title: The Innovative Contributions of Ursula Klingmueller

Introduction

Ursula Klingmueller is a notable inventor based in Heidelberg, Germany. She has made significant contributions to the field of medicine, particularly in the treatment of anemia. Her work focuses on optimizing dosage regimens for erythropoiesis stimulating agents (ESA) in patients suffering from anemia, especially those with cancer.

Latest Patents

Ursula Klingmueller holds a patent for "Methods for the prediction of a personalized ESA-dose in the treatment of anemia." This invention features an integrative pharmacokinetic/pharmacodynamics (PK/PD) ESA-EpoR mathematical model that calculates the binding behavior of ESAs. The methods provided enable clinical practitioners to determine ESA binding sites in patients, allowing for optimized treatment regimens. This is particularly crucial for patients with cancer, as it helps in identifying ESAs that specifically target cells expressing high levels of the EPO receptor.

Career Highlights

Throughout her career, Ursula Klingmueller has worked with esteemed institutions such as Albert-Ludwigs-Universität Freiburg and Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts. Her research has contributed to advancements in personalized medicine and the treatment of anemia.

Collaborations

Ursula has collaborated with notable colleagues, including Andreas Raue and Agustin Rodriguez Gonzalez. Their combined expertise has furthered the development of innovative solutions in the medical field.

Conclusion

Ursula Klingmueller's contributions to the treatment of anemia through her innovative patent demonstrate her commitment to improving patient care. Her work continues to influence the medical community and enhance treatment strategies for those affected by this condition.